FDA expands approval of treatment for cystic fibrosis to include patients ages 6 and older - FDA Press Releases

FDA expanded the indication for Symdeko for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

from FDA Press Releases RSS Feed http://bit.ly/2WWmraE
via IFTTT